Computational Evaluation of Vitamin D3 Binding to KRAS and TGF-β1 in Colorectal Cancer–Associated Signalling Pathways
DOI:
10.29303/jpm.v21i2.11643Published:
2026-04-09Downloads
Abstract
Vitamin D3 has been widely investigated for its anticancer properties, yet the structural basis of its interaction with key oncogenic signaling proteins remains incompletely understood. This study aimed to evaluate the molecular interactions between vitamin D3 and KRAS and TGF-β1 using molecular docking and molecular dynamics simulations. Molecular docking analysis was performed using AutoDock Vina, followed by molecular dynamics simulation using CABS-flex to evaluate structural stability using root mean square deviation (RMSD), root mean square fluctuation (RMSF), and radius of gyration (Rg). Comparative benchmarking was performed against the reference inhibitors Sotorasib (KRAS) and Galunisertib (TGF-β pathway). Docking analysis revealed that vitamin D3 binds to KRAS (PDB ID: 4OBE) with a binding affinity of –7.8 kcal/mol, compared to –8.6 kcal/mol for Sotorasib. The interaction was localized within the nucleotide-binding pocket adjacent to the Switch I and Switch II regions, which are critical for conformational regulation. For TGF-β1 (PDB ID: 3KFD), vitamin D3 demonstrated a binding affinity of –8.2 kcal/mol, slightly exceeding that of Galunisertib (–8.1 kcal/mol), with interaction occurring at the receptor-binding interface. Molecular dynamics simulation showed stable complex formation, with RMSD values of 2.79 Å for the KRAS complex and 1.535 Å for the TGF-β1 complex, indicating acceptable structural stability. Residue fluctuation analysis further supported moderate flexibility without global destabilization. These findings suggest that vitamin D3 may function as a multi-target signaling modulator interacting with both intracellular and extracellular regulators of colorectal cancer pathways, providing a structural basis for further experimental investigation.
Keywords:
Epithelial–Mesenchymal Transition (EMT); KRAS; Molecular Docking; TGF-β1; Vitamin D3References
O. P. Krashenkov, I. O. Ivanikov, I. S. Konstantinova, Y. I. Kochetkova, A. P. Krashenkova, and N. N. Vinogradova, “Organization of oncological care for patients with colorectal cancer (narrative review),” Dokazatel’naya Gastroenterol., vol. 10, no. 1, p. 17, 2021, doi: 10.17116/dokgastro20211001117.
F. Baidoun, K. Elshiwy, Y. Elkeraie, Z. Merjaneh, G. Khoudari, M. T. Sarmini, et al., “Colorectal cancer epidemiology: Recent trends and impact on outcomes,” Curr. Drug Targets, vol. 22, no. 9, pp. 998–1009, 2021, doi: 10.2174/1389450121999201117115717.
H. Postwala, Y. Shah, P. S. Parekh, and M. R. Chorawala, “Unveiling the genetic and epigenetic landscape of colorectal cancer: New insights into pathogenic pathways,” Med. Oncol., vol. 40, no. 11, p. 334, 2023, doi: 10.1007/s12032-023-02201-8.
S. G. Duta-Ion, I. R. Juganaru, I. A. Hotinceanu, A. Dan, L. M. Burtavel, M. C. Coman, et al., “Redefining therapeutic approaches in colorectal cancer: Targeting molecular pathways and overcoming resistance,” Int. J. Mol. Sci., vol. 25, no. 23, p. 12507, 2024, doi: 10.3390/ijms252312507.
A. Setia, S. Bhattacharya, and A. Agrawal, “lncRNA NLIPMT inhibitors in colorectal cancer management,” in Colorectal Cancer Diagnosis and Therapeutic Updates, Singapore: Bentham Science, 2022, pp. 46–70, doi: 10.2174/9789815040944122010010.
Z. Wang, Y. Chang, H. Sun, Y. Li, and T. Tang, “Advances in molecular mechanisms of inflammatory bowel disease-associated colorectal cancer,” Oncol. Lett., vol. 27, no. 6, p. 257, 2024, doi: 10.3892/ol.2024.14390.
C. W. K. Wu, M. Reid, S. Leedham, and R. N. Lui, “The emerging era of personalized medicine in advanced colorectal cancer,” J. Gastroenterol. Hepatol., vol. 37, no. 8, pp. 1411–1425, 2022, doi: 10.1111/jgh.15937.
P. K. Tripathi, K. R. Mittal, N. Jain, N. Sharma, and C. K. Jain, “KRAS pathways: A potential gateway for cancer therapeutics and diagnostics,” Recent Pat. Anticancer Drug Discov., vol. 19, no. 3, pp. 268–279, 2024, doi: 10.2174/1574892818666230406085120.
A. O. Giarratana, C. M. Prendergast, M. M. Salvatore, and K. M. Capaccione, “TGF-β signaling: Critical nexus of fibrogenesis and cancer,” J. Transl. Med., vol. 22, no. 1, p. 594, 2024, doi: 10.1186/s12967-024-05411-4.
N. Sudhakar, L. Yan, F. Qiryaqos, L. D. Engstrom, J. Laguer, A. Calinisan, et al., “The SOS1 inhibitor MRTX0902 blocks KRAS activation and demonstrates antitumor activity,” Mol. Cancer Ther., vol. 23, no. 10, pp. 1418–1430, 2024, doi: 10.1158/1535-7163.MCT-23-0870.
G. Zhu, L. Pei, H. Xia, Q. Tang, and F. Bi, “Role of oncogenic KRAS in prognosis, diagnosis and treatment of colorectal cancer,” Mol. Cancer, vol. 20, no. 1, p. 143, 2021, doi: 10.1186/s12943-021-01441-4.
S. Shi, A. Liu, and Y. Guo, “Elucidating conformational dynamics of GDP/GTP-KRAS complexes,” J. Biomol. Struct. Dyn., pp. 1–22, 2026, doi: 10.1080/07391102.2025.2610685.
K. Zhu, C. Li, K. Y. Wu, C. Mohr, X. Li, and B. Lanman, “Modeling receptor flexibility in KRAS inhibitor design,” J. Comput. Aided Mol. Des., vol. 36, no. 8, pp. 591–604, 2022, doi: 10.1007/s10822-022-00467-0.
D. R. Zhao, J. T. Yang, M. T. Liu, L. Q. Yang, and P. Sang, “Deciphering allosteric mechanisms in KRAS activation,” RSC Adv., vol. 15, no. 3, pp. 2261–2274, 2025, doi: 10.1039/D4RA07924H.
H. Guo et al., “Smad4 regulates TGF-β1-mediated hedgehog activation,” Comput. Struct. Biotechnol. J., vol. 23, pp. 1189–1200, 2024, doi: 10.1016/j.csbj.2024.03.010.
H. Li, H. Chang, Z. Shi, and P. C. K. Leung, “ID3 mediates TGF-β1-induced suppression,” FEBS J., vol. 286, no. 21, pp. 4310–4327, 2019, doi: 10.1111/febs.14964.
H. Sun, S. Wei, and Q. Xi, “TGF-β signaling pathway in development and disease,” Chinese Sci. Bull., vol. 69, no. 30, pp. 4356–4372, 2024, doi: 10.1360/TB-2024-0326.
Ł. Wieteska et al., “Structures of TGF-β with receptors reveal mechanisms,” Nat. Commun., vol. 16, no. 1, p. 1778, 2025, doi: 10.1038/s41467-025-56796-9.
M. Fasano et al., “TGF-β modulated pathways in colorectal cancer,” Int. J. Mol. Sci., vol. 25, no. 13, p. 7400, 2024, doi: 10.3390/ijms25137400.
A. Soleimani et al., “Role of TGF-β signaling pathway in colorectal cancer,” J. Cell Biochem., vol. 120, no. 6, pp. 8899–8907, 2019, doi: 10.1002/jcb.28331.
S. Chamseddine, A. Azmi, and M. W. Saif, “Overview of KRAS-targeting therapies,” Expert Opin. Investig. Drugs, vol. 34, no. 12, pp. 1011–1021, 2025, doi: 10.1080/13543784.2025.2611395.
W. H. Hsu et al., “Oncogenic KRAS drives lipofibrogenesis,” Cancer Discov., vol. 13, no. 12, pp. 2652–2673, 2023, doi: 10.1158/2159-8290.CD-22-1467.
D. J. Flanagan et al., “Epithelial TGFβ engages signaling to drive tumorigenesis,” Nat. Commun., vol. 13, p. 7551, 2022, doi: 10.1038/s41467-022-35134-3.
A. Borojević et al., “Vitamin D3 stimulates proliferation and osteogenesis,” Biomolecules, vol. 12, no. 2, p. 323, 2022, doi: 10.3390/biom12020323.
A. Bahl and V. K. V. Gade, “Vitamin D and malignancies,” in Vitamin D: A Comprehensive Guide, Singapore: Springer, 2025, pp. 185–189, doi: 10.1007/978-981-96-6491-7_16.
P. Uppathi, S. Rajakumari, and K. V. Saritha, “Molecular docking: An emerging tool for cancer therapy,” Crit. Rev. Oncog., vol. 30, no. 1, pp. 1–13, 2025, doi: 10.1615/CritRevOncog.2024056533.
H. Sahakyan, “Improving virtual screening with MM/GBSA,” J. Comput. Aided Mol. Des., vol. 35, no. 6, pp. 731–736, 2021, doi: 10.1007/s10822-021-00389-3.
Y. H. Huang, P. C. Lin, W. C. Su, R. H. Chan, P. C. Chen, B. W. Lin, et al., “Association between altered oncogenic signaling pathways and overall survival of patients with metastatic colorectal cancer,” Diagnostics, vol. 11, no. 12, p. 2308, 2021, doi: 10.3390/diagnostics11122308.
C. Pierro, X. Zhang, C. Kankeu, M. Trebak, M. D. Bootman, and H. L. Roderick, “Oncogenic KRAS suppresses store-operated Ca²⁺ entry,” Cell Calcium, vol. 72, pp. 70–80, 2018, doi: 10.1016/j.ceca.2018.03.002.
R. Yuki, “Aberrant activation mechanism of TGF-β signaling in epithelial–mesenchymal transition,” Yakugaku Zasshi, vol. 141, no. 11, 2021, doi: 10.1248/yakushi.21-00143.
M. H. C. Dorice, N. Khurana, N. Sharma, and G. L. Khatik, “Identification of possible molecular targets using molecular docking technique,” Asian J. Pharm. Clin. Res., vol. 11, 2018, doi: 10.22159/ajpcr.2018.v11s2.28512.
Z. Mohebbinia, R. Firouzi, and M. H. Karimi-Jafari, “Improving protein–ligand docking results using semiempirical quantum mechanics,” J. Biomol. Struct. Dyn., vol. 43, no. 7, pp. 3602–3612, 2025, doi: 10.1080/07391102.2023.2299742.
D. Pandey and K. K. Roy, “Decoding KRAS dynamics: Exploring mutation and inhibitor binding,” Arch. Biochem. Biophys., vol. 764, p. 110279, 2025, doi: 10.1016/j.abb.2024.110279.
K. Y. Lee, “Membrane-driven dimerization of KRAS,” Int. J. Mol. Sci., vol. 25, no. 5, p. 2530, 2024, doi: 10.3390/ijms25052530.
K. Miyazono, T. Ito, Y. Fukatsu, H. Wada, A. Kurisaki, and M. Tanokura, “Structural basis for transcriptional coactivator recognition by SMAD2,” Sci. Signal., vol. 13, no. 662, 2020, doi: 10.1126/scisignal.abb9043.
S. Bagheri, H. Behnejad, R. Firouzi, and M. H. Karimi-Jafari, “Using semiempirical quantum mechanics in improving molecular docking,” Mol. Inform., vol. 39, no. 9, 2020, doi: 10.1002/minf.202000036.
M. A. Herdiansyah et al., “Molecular interaction analysis of ferulic acid against MCF-7 receptors,” Narra J., vol. 4, no. 2, p. e775, 2024, doi: 10.52225/narra.v4i2.775.
M. R. T. Alifiansyah et al., “QSAR of acyl alizarin red derivatives and ADMET properties,” Food Syst., vol. 7, no. 2, pp. 312–320, 2024, doi: 10.21323/2618-9771-2024-7-2-312-320.
V. Innao et al., “Vitamin D substitution in monoclonal gammopathies,” Int. J. Mol. Sci., vol. 22, no. 9, p. 4922, 2021, doi: 10.3390/ijms22094922.
J. E. Varghese et al., “Role of vitamin D3 on apoptosis and inflammation in colorectal cancer,” J. King Saud Univ. Sci., vol. 32, no. 6, pp. 2786–2789, 2020, doi: 10.1016/j.jksus.2020.06.015.
S. Yiyan et al., “Vitamin D regulates PI3K/AKT/mTOR pathway in cancer cells,” Curr. Cancer Drug Targets, vol. 22, no. 1, pp. 86–95, 2022, doi: 10.2174/1568009621666210729100300.
M. A. Zmijewski and C. Carlberg, “Vitamin D receptor(s): In the nucleus and membranes,” Exp. Dermatol., vol. 29, no. 9, pp. 876–884, 2020, doi: 10.1111/exd.14147.
Z. Sakhi et al., “Role of vitamin D supplementation in cancer treatment,” in Cancer Biomarkers and Oncoviruses, Elsevier, 2026, pp. 467–479, doi: 10.1016/B978-0-443-30225-1.00034-8.
J. Blasiak et al., “Vitamin D protection against breast cancer via lncRNA regulation,” Int. J. Mol. Sci., vol. 23, no. 6, p. 3189, 2022, doi: 10.3390/ijms23063189.
F. H. Shahraki et al., “Molecular interaction between vitamin D3 and pepsin,” Spectrochim. Acta A, vol. 334, p. 125956, 2025, doi: 10.1016/j.saa.2025.125956.
J. Shobahah et al., “In silico evaluation of vitamin D3 as dual inhibitor in colorectal cancer,” Open Vet. J., vol. 15, no. 8, p. 3759, 2025, doi: 10.5455/OVJ.2025.v15.i8.40.
Y. Song et al., “Molecular basis of vitamin D3 interactions with AhR,” Int. J. Biol. Macromol., vol. 209, pp. 1111–1123, 2022, doi: 10.1016/j.ijbiomac.2022.04.048.
A. Madamanchi et al., “Computational modeling of TGF-β receptor complex assembly,” Biophys. J., vol. 122, no. 7, pp. 1342–1354, 2023, doi: 10.1016/j.bpj.2023.02.030.
Y. Li, R. He, and L. Mishra, “TGF-β signaling in stem cells and tumorigenesis,” in Molecular Oncology, Cambridge Univ. Press, 2013, pp. 119–134.
D. Pourjafar-Dehkordi and M. Zacharias, “Influence of phosphorylation on Rab1b dynamics,” Proteins, vol. 89, no. 10, pp. 1324–1332, 2021, doi: 10.1002/prot.26153.
S. Senyuz et al., “Mechanistic differences of Rac1 activation,” J. Phys. Chem. B, vol. 125, no. 15, pp. 3790–3802, 2021, doi: 10.1021/acs.jpcb.1c00883.
M. Zhang, H. Jang, and R. Nussinov, “Structural basis for Ras activation of PI3Kα,” Phys. Chem. Chem. Phys., vol. 21, no. 22, pp. 12021–12028, 2019, doi: 10.1039/C9CP00101H.
A. Chour et al., “KRAS mutation in lung cancer management,” Rev. Mal. Respir., vol. 17, no. 2, pp. 2S221–2S229, 2025, doi: 10.1016/S1877-1203(25)00078-3.
H. Hoshiyama, “Pharmacological characteristics of KRAS inhibitor sotorasib,” Folia Pharmacol. Jpn., vol. 158, no. 5, 2023, doi: 10.1254/fpj.22148.
H. N. Kim et al., “Switch II pocket inhibitor arrests KRAS GTPase cycle,” J. Mol. Biol., vol. 437, no. 14, p. 169162, 2025, doi: 10.1016/j.jmb.2025.169162.
M. Cefalì et al., “Research progress on KRAS mutations in colorectal cancer,” J. Cancer Metastasis Treat., 2021, doi: 10.20517/2394-4722.2021.61.
B. A. Bye et al., “Combined Omipalisib and MAPK inhibition suppress PDAC growth,” Cancers, vol. 17, no. 7, p. 1152, 2025, doi: 10.3390/cancers17071152.
A. B. Baba et al., “TGF-β signaling in cancer,” Front. Pharmacol., vol. 13, 2022, doi: 10.3389/fphar.2022.791272.
S. Gu and X. H. Feng, “TGF-β signaling in cancer,” Acta Biochim. Biophys. Sin., vol. 50, no. 10, pp. 941–949, 2018, doi: 10.1093/abbs/gmy092.
D. Prasanth et al., “Vitamin D-induced mechanisms in cancer prevention,” Anim. Model Exp. Med., vol. 8, no. 11, pp. 1935–1946, 2025, doi: 10.1002/ame2.70087.
K. S. Wakle et al., “Vitamin D3 anticancer mechanisms in MCF-7 cells,” Mol. Divers., 2025, doi: 10.1007/s11030-025-11156-z.
Y. Wang et al., “Vitamin D3 promotes gastric cancer autophagy,” Front. Pharmacol., vol. 14, 2024, doi: 10.3389/fphar.2023.1338260.
P. Vanclooster et al., “RAS-directed therapies in gastrointestinal malignancies,” Curr. Opin. Oncol., vol. 36, no. 4, pp. 313–319, 2024, doi: 10.1097/CCO.0000000000001042.
L. Vuong, H. Chu, and Q. Nguyen, “Genetic abnormalities in colorectal cancer patients,” J. Adv. Biotechnol. Exp. Ther., vol. 5, no. 2, p. 408, 2022, doi: 10.5455/jabet.2022.d124.
Z. Sheng et al., “Molecular basis of oncogenic PI3K proteins,” Cancers, vol. 17, no. 1, p. 77, 2024, doi: 10.3390/cancers17010077.
M. Sattler et al., “Precision oncology targeting KRAS resistance,” Trends Cancer, vol. 9, no. 1, pp. 42–54, 2023, doi: 10.1016/j.trecan.2022.10.001.
C. Hoyek et al., “Advances in targeting KRAS G12C,” Oncol. Haematol., vol. 20, no. 2, pp. 25–33, 2024, doi: 10.17925/OHR.2024.20.2.7.
T. Koga and T. Mitsudomi, “Lung cancer and KRAS molecular biology,” Haigan, vol. 62, no. 3, pp. 188–199, 2022, doi: 10.2482/haigan.62.188.
M. Nagasaka et al., “KRAS G12C inhibitor landscape,” Cancer Treat. Rev., vol. 84, p. 101974, 2020, doi: 10.1016/j.ctrv.2020.101974.
F. Negri et al., “KRAS: A druggable target in colon cancer,” Int. J. Mol. Sci., vol. 23, no. 8, p. 4120, 2022, doi: 10.3390/ijms23084120.
A. Ahmadi et al., “TGF-β signaling in tumorigenesis and therapy,” J. Cell Physiol., vol. 234, no. 8, pp. 12173–12187, 2019, doi: 10.1002/jcp.27955.
J. Liu et al., “TGF-β in tumor development and progression,” Mol. Biomed., vol. 7, no. 1, p. 9, 2026, doi: 10.1186/s43556-026-00403-w.
License
Copyright (c) 2026 Jauharotus Shobahah, Wahyuningsih Sri Puji Astuti , Mochammad Aqilah Herdiansyah, M. Ainun Najib Aly
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
Downloads
How to Cite
